Tumor-intrinsic FDFT1 determines coordinated macrophage anti-tumor immunity
Developmental Cell · 2026-06 · 61 (6) · 1238-1253.e7
DOI: 10.1016/j.devcel.2026.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Cell, 2026-06. Verfasst von Rongchen Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, College of High Altitude Military Medicine, Third Military Medical University (Army Medical University), Chongqing 400…. Hauptthemen laut MEDLINE: Macrophages, Farnesyltranstransferase, Neoplasms. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Chongqing Natural Science Foundation, National Major Science and Technology Projects of China, National Outstanding Youth Foundation of China.
Abstract (Originalsprache)
Macrophage anti-tumor efficacy requires coordinated inflammatory activation and phagocytic function, whether a tumor-intrinsic metabolic regulator simultaneously determines both macrophage anti-tumor mechanisms remains unclear. Here, we screened and identified that farnesyl-diphosphate farnesyltransferase 1 (FDFT1) drives the dual inhibition of macrophage activation and phagocytic function and promotes tumor progression. Mechanistically, tumor-intrinsic FDFT1 directly binds to STAT3 and facilitates the later phosphorylation, which induces PD-L1-dependent suppression of macrophage phagocytosis. Concurrently, FDFT1 binds to and stabilizes cholesterol 25-hydroxylase (CH25H) to promote the secretion of 25-hydroxycholesterol (25HC), suppressing proinflammatory activation of macrophages. Furthermore, FDFT1-mediated dual anti-tumor pathways were validated in mouse tumor models and correlated with clinical pathophysiology. Notably, a small-molecule drug FDFT1-I (2123) targeting FDFT1 inhibits both STAT3-PD-L1 and CH25H/25HC pathways and improves anti-tumor immunity. Collectively, our findings highlight FDFT1 as a tumor-intrinsic metabolic factor promoting tumor development via dual macrophage-dependent mechanisms, suggesting FDFT1 as a promising target for tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, College of High Altitude Military Medicine, Third Military Medical University (Army Medical University), Chongqing 400038, China; Key Laboratory of Extreme Environmental Medicine, Ministry…
- College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing 400038, China.
- Department of Clinical Laboratory, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.
- Department of Colorectal Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department o…
Förderung
- Chongqing Natural Science Foundation
- National Major Science and Technology Projects of China
- National Outstanding Youth Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Shi, R., Huang, Y., Zheng, P., Zhang, D., Qin, Q., Zhang, F., Wang, M., Zhao, K., Yang, M., Guan, X., Deng, R., & Miao, H. (2026). Tumor-intrinsic FDFT1 determines coordinated macrophage anti-tumor immunity. Developmental Cell, 61(6), 1238-1253.e7. https://doi.org/10.1016/j.devcel.2026.04.003
Vancouver
Shi R, Huang Y, Zheng P, Zhang D, Qin Q, Zhang F, et al. Tumor-intrinsic FDFT1 determines coordinated macrophage anti-tumor immunity. Developmental Cell. 2026;61(6):1238-1253.e7. doi:10.1016/j.devcel.2026.04.003
BibTeX
@article{Shi2026,
author = {Shi, Rongchen and Huang, Yulan and Zheng, Pengfei and Zhang, Dapeng and Qin, Qing and Zhang, Fan and Wang, Meng and Zhao, Kun and Yang, Minli and Guan, Xu and Deng, Renchao and Miao, Hongming},
title = {Tumor-intrinsic FDFT1 determines coordinated macrophage anti-tumor immunity},
journal = {Developmental Cell},
year = {2026},
volume = {61},
number = {6},
pages = {1238--1253.e7},
doi = {10.1016/j.devcel.2026.04.003}
}
EUVIMED